



Iron(II) supramolecular helicates interfere with the
HIV-1 Tat–TAR RNA interaction critical for viral
replication




Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Hannon, M, Malina, J & Brabec, V 2016, 'Iron(II) supramolecular helicates interfere with the HIV-1 Tat–TAR RNA
interaction critical for viral replication', Scientific Reports, vol. 6, 29674 . https://doi.org/10.1038/srep29674
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
1Scientific RepoRts | 6:29674 | DOI: 10.1038/srep29674
www.nature.com/scientificreports
Iron(II) supramolecular helicates 
interfere with the HIV-1 Tat–TAR 
RNA interaction critical for viral 
replication
Jaroslav Malina1, Michael J. Hannon2 & Viktor Brabec1,3
The interaction between the HIV-1 transactivator protein Tat and TAR (transactivation responsive 
region) RNA, plays a critical role in HIV-1 transcription. Iron(II) supramolecular helicates were evaluated 
for their in vitro activity to inhibit Tat–TAR RNA interaction using UV melting studies, electrophoretic 
mobility shift assay, and RNase A footprinting. The results demonstrate that iron(II) supramolecular 
helicates inhibit Tat-TAR interaction at nanomolar concentrations by binding to TAR RNA. These studies 
provide a new insight into the biological potential of metallosupramolecular helicates.
The trans activation response region (TAR) of RNA (Fig. 1b) represents an attractive target for the inhibition 
of human imunodeficiency virus type 1 (HIV-1) replication by small molecules. The binding of the viral trans 
activator protein (Tat) to the TAR RNA is an essential step in the HIV-1 replication cycle. Therefore, the blockage 
of the Tat-TAR interaction is a potential route for AIDS chemotherapy. Compounds that bind to TAR RNA, and 
prevent binding by Tat, could disrupt processive transcription and thereby inhibit viral growth1.
Tat binds to TAR RNA at the three-nucleotide pyrimidine bulge and interacts with two base pairs above and 
below the bulge in the major groove of the TAR RNA molecule2,3. Upon binding of Tat, TAR RNA undergoes a 
distinct conformational change characterized by a significant compression of the protein binding pocket at the 
pyrimidine bulge4,5. Numerous small molecules and peptides that bind three-nucleotide bulges have been syn-
thesized and tested in the past6–10, but many of these molecules did not have sufficient potency to progress into 
pharmaceutical development11.
We have shown that dinuclear iron (II) metallosupramolecular triple helicates [Fe2L3]Cl4 (L = C25H20N4, 
Fig. 1a) can specifically recognize various unusual DNA or RNA structures, such as Y-shaped three-way junc-
tions12–14, three-way junctions containing unpaired nucleotides, the so-called T-shaped three-way junctions15 
and others also studied binding to human telomeric G-quadruplex DNA16. Interestingly, these helicates, similarly 
as a flexibly-linked dinuclear ruthenium(II) complex17,18, can also bind nucleic acids bulges containing two or 
more unpaired nucleotides19. The three-nucleotide pyrimidine bulge in TAR RNA represents a binding site for 
the recruitment of the viral transactivator protein Tat. For this reason we were intrigued to see if the cylindrical 
helicates would bind to the bulge of TAR RNA and in this way could block the Tat-TAR RNA interaction.
Here, we report on the interactions of M- and P-enantiomers of [Fe2L3]Cl4 with the TAR RNA by using ther-
mal denaturation, electrophoretic mobility shift assay, and RNase A footprinting. In addition, we used the ADP-1 
polypeptide (Fig. 1c) that carries the minimal RNA recognition region of the Tat protein and closely mimics Tat 
binding specificity3,4 to investigate whether the helicates can inhibit formation of the Tat-TAR RNA complex.
Results and Discussion
Binding of the helicates to the HIV-1 TAR RNA. UV melting studies. The ability of M- and P-[Fe2L3]
Cl4 to alter the melting temperature (Tm) of TAR RNA reflects to some extend the strength of binding. The melt-
ing curves of TAR RNA and fully matched RNA duplex (Fig. 1b) in the absence and presence of the helicates are 
shown in Supplementary Figs S1and S2 online. The Δ Tm (Tm of the helicate-RNA complex - Tm of the free RNA) 
values are presented in Table 1.
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The melting temperatures of the TAR RNA and fully matched RNA duplex in the absence of the helicates 
were 67.4 °C and 65.7 °C, respectively. The presence of M- and P-[Fe2L3]Cl4 increased the Tm of the TAR RNA by 
12.1 °C and 11.2 °C at 1:1 helicate:RNA ratio, respectively, and by 13.3 °C and 12.9 °C at 2:1 helicate:RNA ratio, 
respectively. Doubling the helicate:RNA ratio from 1:1 to 2:1 had little effect (< 2 °C) on the thermal stability of 
the TAR RNA, which indicates that there is a single dominant binding site for the helicates on the TAR RNA. The 
Tm values of the fully matched RNA duplex were affected only negligibly by the presence of the helicates.
Binding constants (K) of the helicates to TAR RNA, calculated from ethidium bromide displacement experi-
ments (Supplementary Fig. S3) revealed that both M-[Fe2L3]Cl4 and P-[Fe2L3]Cl4 helicates exhibit similar binding 
affinities for the TAR RNA (the values of K were 190 ± 10 × 106 M−1 and 222 ± 13 × 106 M−1 for the M- and 
P-enantiomer, respectively).
Electrophoretic mobility shift assay. An electrophoretic mobility shift assay (EMSA) was used to explore the sta-
bility of the helicate:TAR RNA complex. The autoradiogram of the electrophoresis gel run at 5 °C (Fig. 2) shows 
the interaction of the TAR RNA with increasing concentrations of M- and P-[Fe2L3]Cl4. It can be seen that a new, 
more slowly migrating band indicating the formation of the helicate:TAR RNA complex appears in the gel in the 
presence of the helicates.
Inspection of the gel in Fig. 2 also shows that when the helicate:TAR RNA ratio exceeds 1:1 no additional 
bands indicating the formation of the TAR RNA complex with two molecules of [Fe2L3]4+ appear in the gel.
It supports the presence of only one major binding site for the helicates on the TAR RNA. We performed the 
same experiment under the same conditions using the fully matched RNA duplex but no new bands correspond-
ing to the formation of the helicate:RNA complex were observed in the gel (see Supplementary Fig. S4).
Figure 1. Structures of helicates, RNA nucleotide sequences and amino acid sequence of the ADP-1 
polypeptide. (a) Structures of the ligand L and the tetracataionic triple helicate M-[Fe2L3]4+ formed from that 
ligand [adapted from Protein Data Bank (PDB) file 2ET0]. (b) Sequences of the TAR RNA, containing residues 
18–44 of HIV-1 mRNA and two additional G·C base pairs, and the fully matched RNA duplex. (c) The sequence 
of the ADP-1 polypeptide carrying the minimal RNA recognition region of the Tat protein (residues 37–72) and 
closely mimicking Tat binding specificity.
Compound ΔTm (°C) at 1:1a ΔTm (°C) at 2:1b
TAR RNA (Tm = 67.4 °C)
 M-[Fe2L3]Cl4 12.1 13.3
 P-[Fe2L3]Cl4 11.2 12.8
Fully matched RNA duplex (Tm = 65.7 °C)
 M-[Fe2L3]Cl4 − 0.5 − 1.0
 P-[Fe2L3]Cl4 − 0.1 0.5
Table 1.  Thermal stability of the fully matched RNA duplex and the TAR RNA in the presence of M- and P-
[Fe2L3]Cl4. aHelicate:duplex was 1:1. bHelicate:duplex was 2:1.
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RNase A footprinting. In order to identify potential binding sites of M- and P-[Fe2L3]Cl4 on the TAR RNA, we 
probed the helicate:TAR RNA complexes with RNase A. Since this enzyme prefers cleavage of single-stranded 
to double-stranded regions of the RNA, it is particularly well suited for investigating drug binding to the single 
stranded parts, including the bulge and loop regions. The autoradiogram of the RNA cleavage-inhibition patterns 
for the TAR RNA is shown in Fig. 3. The strong cleavage at positions 23–26 corresponding to the 5′ -UCU bulge is 
markedly reduced in the presence of both enantiomers of [Fe2L3]Cl4. In contrast, the cutting is increased between 
nucleotides C30 and U31 located in the loop. It is likely that the base protection effects induced by the helicates 
result from the direct interaction with the helicates, but it cannot be excluded that the protection arises from 
helicate-induced structural changes. In any case, the results of the RNase A footprinting suggest that the M- and 
P-[Fe2L3]Cl4 preferentially bind to the TAR RNA bulge or in its close proximity.
Inhibition of the HIV-1 Tat-TAR interaction. The EMSA was also employed to determine if the binding of the 
helicates to the TAR RNA can inhibit the Tat-TAR interaction. In these experiments, we used the ADP-1 polypep-
tide (see Fig. 1c for its sequence) that has been previously demonstrated4 to carry the minimal RNA recognition 
region of the HIV-1 Tat protein and closely mimic Tat binding specificity. The autoradiogram in Fig. 4a presents 
binding of the ADP-1 to the TAR RNA in the absence of the helicates. The autoradiogram in Fig. 4b shows how 
the formation of the ADP-1-TAR RNA complex is inhibited in the presence of M- and P-[Fe2L3]Cl4. It can be 
Figure 2. Binding of the helicates to TAR RNA. Autoradiogram of the gel run at 5 °C showing binding of the 
helicates to TAR RNA (2 μ M). Lane C: TAR-RNA in the absence of the helicates. Lanes 1–6: TAR RNA mixed 
with M-[Fe2L3]Cl4 at 0.25:1, 0.5:1, 0.75:1, 1:1, 1.5:1 and 2:1 (helicate:TAR RNA) ratios, respectively. Lanes 
7–12: TAR RNA mixed with P-[Fe2L3]Cl4 at 0.25:1, 0.5:1, 0.75:1, 1:1, 1.5:1 and 2:1 (helicate:TAR RNA) ratios, 
respectively.
Figure 3. RNase A cleavage of TAR RNA in the presence of helicates. RNase A cleavage of 5′ -32P end-labeled 
TAR RNA (2 μ M) in the presence of increasing concentrations of M- and P-[Fe2L3]Cl4. Lane C; TAR RNA 
cleaved by RNase A in the absence of helicates. Lanes 1–4; TAR RNA mixed with M-[Fe2L3]Cl4 at 0.5:1, 1:1, 
1.5:1, and 2:1 (helicate:TAR RNA) ratios, respectively, cleaved by RNase A. Lanes 5–8; TAR RNA mixed with P-
[Fe2L3]Cl4 at 0.5:1, 1:1, 1.5:1, and 2:1 (helicate:TAR RNA) ratios, respectively, cleaved by RNase A. Lane C0; TAR 
RNA in the absence of helicates and RNase A. Phosphodiester bonds cleaved by RNase A are indicated on the 
left side of the gel.
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seen that the ADP-1-TAR RNA interaction is almost completely inhibited in the presence of both enantiomers 
at the concentration of 16 nM. It might be possible that the helicates disrupt formation of the ADP-1-TAR com-
plex by binding to the peptide rather than to the TAR-RNA. In order to probe this eventuality, we recorded CD 
spectra of M-[Fe2L3]Cl4 at constant helicate concentration (14 μ M) and increasing ADP-1 concentrations (see 
Supplementary Fig. S5). No changes in the CD spectra were noticed with increasing concentrations of ADP-1, 
which is consistent with the view that the helicates did not bind significantly to ADP-1 peptide under conditions 
of our experiments.
In conclusion, our results show that both M- and P-[Fe2L3]Cl4 bind with high affinity to the TAR RNA and dis-
criminate this three-base bulge containing RNA against fully matched RNA duplex. It is reasonable to expect that 
the substantial contribution to the binding affinity of the helicates to TAR RNA comes from their strong binding 
affinity to the structural motif, such as the triangular prismatic pocket formed by the unpaired bulge bases, to 
accommodate the helicate molecule19. RNase A footprinting indicates that helicates bind directly to the 5′ -UCU 
bulge or in its close proximity. Furthermore, our results demonstrate that nanomolar concentrations of both 
enantiomers disrupt formation of the Tat-TAR complex in a purified protein-RNA system. Thus, iron(II) supra-
molecular helicates inhibit the HIV-1 Tat-TAR interaction at notably lower concentrations than many inhibitors 
of Tat-TAR binding so far tested11,20–23. Iron(II) supramolecular helicates provide reasonable templates for further 
developing TAR ligands with improved efficiency and selectivity capable of inhibiting the functions of their RNA 
target. Further investigation of these helicates and their new derivatives more selective for TAR RNA in HIV-
1-infected cellular environments is required for better understanding of their efficacies in HIV-1 therapy which 
can lead to the discovery of novel and highly potent antivirals.
Methods
Chemicals. The iron(II) helicates [Fe2L3]Cl4 (L = C25H20N4; Fig. 1a) were synthesised as previously 
described24–26. The synthetic oligoribonucleotides used in this work were purchased from VBC-Biotech (Vienna, 
Austria). The ADP-1 polypeptide (Fig. 1c) was purchased from Schafer-N (Copenhagen, Denmark) and was 
> 95% pure. T4 polynucleotide kinase was purchased from New England Biolabs (Beverly, MA). [γ -32P]-ATP was 
from MP Biomedicals, LLC (Irvine, CA). Acrylamide and bis(acrylamide) were from Merck KgaA (Darmstadt, 
Germany). RNase A was from Roche (Mannheim, Germany).
UV melting experiments. The stability of DNA bulges in the presence of the helicates was monitored by 
measuring the absorbance at 260 nm (1 nm bandwidth, average time: 10 s, heating rate 0.4 °C/min) as a func-
tion of temperature. The experiment was run simultaneously on six masked 1 cm pathlength microcuvettes of 
0.2 mL volume using a Peltier controlled 6-sample cell-changer in a Varian Cary 4000 UV/vis spectrophotometer. 
Melting temperature (Tm) was calculated within the thermal heating program by applying a first derivative cal-
culation. The Tm values could be determined with an accuracy of ± 0.5 °C. Each DNA melting experiment was 
Figure 4. Formation of the complex between the ADP-1 peptide and TAR RNA and inhibition of the 
formation of the complex by helicates. (a) Binding of the ADP-1 peptide to the TAR RNA (2 nM). Lane C; 
TAR RNA in the absence of the ADP-1. Lanes 1–6; TAR RNA in the presence of 0.5, 1, 2, 4, 8, and 16 nM ADP-1, 
respectively. (b) Inhibition of the complex between the ADP-1 peptide (4 nM) and TAR RNA (2 nM) by M- and 
P-[Fe2L3]Cl4. Lane C; TAR RNA in the absence of the ADP-1 and helicates. Lanes 1–5; TAR RNA mixed with 
the ADP-1 and increasing concentrations (1, 2, 4, 8, and 16 nM, respectively) of M-[Fe2L3]Cl4. Lanes 6–10; TAR 
RNA mixed with the ADP-1 and increasing concentrations (1, 2, 4, 8, and 16 nM, respectively) of P-[Fe2L3]Cl4.
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carried out at least three times and the Tm values represent the mean. The concentration of oligoribonucleotides 
was 3 μ M per strand. The buffer conditions were sodium phosphate buffer (10 mM, pH 7.0) and 0.5 mM EDTA.
Electrophoretic mobility shift assays. RNA was 5′ -end labeled using T4 polynucleotide kinase and 
[γ -32P]ATP and then it was purified by denaturing polyacrylamide gel electrophoresis (PAGE). The RNA con-
centration was determined by the UV absorbance at 260 nm. RNA was annealed by heating at 90 °C and slow 
cooling to room temperature in sterile water. RNA, helicates, and the ADP-1 peptide were mixed in a buffer (5 μ L) 
containing Tris-HCl (50 mM, pH 8.0), KCl (50 mM), DTT (100 mM), and Triton X-100 (0.05%) and incubated 
for 10 min on ice. The samples were analysed by electrophoresis on 15% polyacrylamide (PAA) gels in 0.5 × TB 
buffer and electrophoresed at 5 W and 5 °C. Gels were exposed to a phosphor imaging plate and scanned with a 
FUJIFILM BAS-2500 bio-imaging analyzer.
RNase A footprinting. TAR RNA was 5′ -end labeled using T4 polynucleotide kinase and [γ -32P]ATP and 
then purified by denaturing PAGE. TAR RNA was annealed by heating at 90 °C and slow cooling to room tem-
perature in sterile water. 5 μ L solutions containing 2 × 10−6 M TAR RNA in 10 mM Tris-HCl (pH 7.4) and various 
concentrations of the helicates were incubated for 10 min at 25 °C. Cleavage was initiated by the addition of 1 μ L 
of RNase A diluted in the precedent experiment to the concentration (5 × 10−7 unit) that was sufficient to achieve 
partial cleavage of the TAR RNA. Samples were allowed to react for 5 min at room temperature before quenching 
with 5 μ L of 2× concentrated formamide loading buffer followed by incubation at 90 °C for 3 min. 2 μ L of the 
mixture containing RNA cleavage products were then withdrawn and resolved by PAGE under denaturing con-
ditions (24%/8 M urea PAA gel). Gels were exposed to a phosphor imaging plate and scanned with a FUJIFILM 
BAS-2500 bio-imaging analyzer.
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